Opis projektu
Nowy model opracowywania leków przeciw chorobie układu sercowo-naczyniowego
Choroby układu sercowo-naczyniowego są przyczyną 45 % wszystkich zgonów w Europie, a kwota, którą obciążają co roku europejską gospodarkę to 210 mld EUR. W związku z tym konieczne jest opracowanie lepszych i tańszych metod leczenia. Niestety w ostatniej dekadzie do obrotu dopuszczono zaledwie cztery leki przeciw tym chorobom. Istnieje pilna potrzeba przyspieszenia prac nad nowymi środkami leczniczymi. Celem finansowanego ze środków UE projektu EMAPS-Cardio jest opracowanie nowej platformy typu „narząd na chipie”, która umożliwi hodowanie i dojrzewanie mikrotkanek sercowych na potrzeby organotypowych modeli dojrzałych narządów w stanach zdrowia i choroby. Zwiększenie czułości i dokładności urządzeń typu „narząd na czipie” przyniesie wyczekiwany przełom technologiczny, który przyspieszy rozwój nowych leków i wyeliminuje konieczność stosowania modeli zwierzęcych.
Cel
Cardiovascular diseases (CVDs) account for 45% of deaths in Europe and are estimated to cost the EU economy €210 billion a year. However, only four drugs targeting cardiovascular diseases have been approved for use in the last decade. Thus, models that could effectively simulate diseased tissues, would enable the accurate assessment of the efficacy of the pharmaceuticals, and would accelerate drug development are urgently needed. The main bottleneck towards such models is the foetal-like state of the human induced pluripotent stem cell (hiPSC) derived cardiomyocytes (CMs). That is hiPSC-CMs do not reach adult-like maturity. The objective of this project is to produce a platform for growth and maturation of cardiac microtissues for adult-like organotypic models in healthy and diseased states. To achieve that, biomimetic microenvironment that provides all the needed stimuli (electrical, mechanical, topological (3D environment) and biochemical (release of active molecules)), during the maturation of hiPSC-CMs will be developed. This will be achieved by combining electro-mechanoactive polymer-based scaffolds (EMAPS) with bioactive membranes. To characterize the effects of CVD drugs, the contractility of the microtissue will be monitored continuously and simultaneously (over 24-wells) using the sensors developed during the project. To increase the sensitivity and accuracy of the model, deep-learning based algorithms to detect the effects of drugs in vitro will be developed and verified. The goals will be achieved by a multidisciplinary consortium with complementary know-how of three academic units and seven small companies. The increased sensitivity and accuracy of organ-on-chip devices is a needed leap in technology that will accelerate new drug development without the need for animal models; the project aims to provide a platform for the realization of such physiologically-relevant organotypic models.
Dziedzina nauki
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- engineering and technologyother engineering and technologiesmicrotechnologyorgan on a chip
Słowa kluczowe
Program(-y)
Zaproszenie do składania wniosków
Zobacz inne projekty w ramach tego zaproszeniaSzczegółowe działanie
H2020-NMBP-TR-IND-2020-twostage
System finansowania
RIA - Research and Innovation actionKoordynator
75794 Paris
Francja